ARTICLE AD BOX
Gilead Sciences, the American biotechnology company is slightly undervalued, according to Wolfteam Ltd.'s projections and estimates.
With 27.12 billion USD revenue, declining at -0.60 % with net profit margin of 20.89 %, Gilead Sciences' intrinsic value is 108 billion USD compared to Gilead Sciences' current market capitalization of 90.40 billion USD.
Here is an excerpt from Gilead Sciences first quarter 2024 earnings report:
GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion
Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion
Oncology Sales Increased 18% Year-Over-Year to $789 million
Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact
English (US) ·